Acute myeloid leukemia (AML) with inversion of chromosome 16 inv(16)(p13q22) or balanced translocation t(16;16)(p13;q22), which results in the fusion of CBFB to MYH11, is closely associated with a favorable outcome compared with other AML subtypes, especially when patients are treated with high-dose cytarabine (HD-AraC) consolidation therapy. However, relapse still occurs in 30-40% of cases and a significant number of patients subsequently die. An adequate prediction of relapse risk could justify alternative therapy strategies in first complete remission (CR), including allogeneic hematopoietic stem cell transplantation. Prognostic factors for risk of relapse in this AML subset are still a matter of debate. Mutations in receptor tyrosine kinase genes, including c-KIT and FLT3, are present in about 20-30% of inv(16)/t(16;16) AML cases. In a recent report of the Cancer and Leukemia Group B, the relapse risk was higher for patients with c-KIT mutations. 1 Minimal residual disease (MRD) monitoring is of growing importance for risk stratification and early detection of relapse in AML. Previous studies reported the feasibility and the potential prognostic impact of MRD detection using real-time PCR or quantitative real-time PCR (RQ-PCR), but produced conflicting results. Low MRD level after induction or following completion of the entire chemotherapy program was associated with a lower risk of relapse.
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previously described a strong prognostic impact of the initial fusion transcript level by creating a score based on the median expression ratio after consolidation therapy and the 75th percentile of the expression ratio at diagnosis. However, no study has defined an absolute threshold for the early molecular response, which could be used for outcome prediction. Furthermore, no prognostic analysis taking into account all previous prognostic factors including MRD and mutational profile is available and the clinical relevance of monitoring MRD by RQ-PCR is still a matter of debate in this AML subset. In this study, we retrospectively analyzed the prognostic value of sequential MRD assessment by RQ-PCR in patients with CBFB-MYH11-positive AML with known c-KIT, FLT3 and RAS mutational status. A total of 59 AML patients with inv(16)/ t(16;16) diagnosed between 1993 and 2008 in 14 French University Hospitals and who achieved first CR using cooperative group multicenter trials were retrospectively analyzed. The main characteristics of the patients are described in Table 1 . In agreement with the declaration of Helsinki, patients or their guardians (for children) gave informed consent for the use of their samples in research studies. Patients were treated according to the clinical trials of the Acute Leukemia French Association (ALFA) or the European Organisation for the Research and Treatment of Cancer (EORTC) cooperative groups for adult cases and of the Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Group for pediatric cases. Although these trials evolved during the patient recruitment period, HD-AraC was given during consolidation to 79% of patients. Intensification chemotherapy followed by autologous stem cell transplantation was used as consolidation therapy in four patients. Two pediatric cases received allogeneic hematopoietic stem cell transplantation with a matched related donor in first CR; CR status and survival data were censored at the time of transplant in both cases. Peripheral blood (PB) and bone marrow (BM) samples were collected at diagnosis, at CR achievement (MRD1), after the first consolidation course (MRD2), after the end of consolidation chemotherapy (MRD3) and every 3-6 months thereafter. The decrease in MRD2 (DMRD2) was defined as MRD2/CBFB-MYH11 transcript level at diagnosis. A total of 515 consecutive PB or BM samples were centralized and prospectively analyzed according to the same techniques in three French laboratories (CHRU of Lille, Paris Necker and Paris Saint-Louis Hospitals). RQ-PCR was performed following the Europe Against Cancer program recommendations for CBFB-MYH11 fusion transcripts. 6 As the genomic break points within the CBFB and MYH11 genes are variable, at least 11 different types of CBFB-MYH11 fusion transcripts (that is, A to K) have been described, although the type A largely Letters to the Editor predominates. Specifics primers were used to detect A, D and E transcripts, that is, the most common ones. A specific reverse primer was designed (5 0 -CGTAGACACGTTGAGCTTCTGC-3 0 ) for the detection of type J transcript. Results were expressed by the ratio CBFB-MYH11 copy number/ABL copy number Â 100 (%), according to a standard curve established with serial dilutions of CBFB-MYH11 and ABL Ipsogen plasmids. FLT3, c-KIT and RAS mutations were detected in BM or PB samples as previously reported.
7 Pretreatment CBFB-MYH11 transcript level showed large variations, ranging from 26 to 620% (median: 107%). MRD1 (median: 0, 24%, ranging from 0 to 11%) was available in 48 patients (42 BM and 6 PB samples) and MRD2 (median: 0, 1%, ranging from 0 to 5.4%) in 49 patients (34 BM and 15 PB samples). MRD3, available in 55 patients, was still positive for 17 patients. Forty-three paired analyses of diagnostic BM and PB samples were correlated. For positive MRD levels (40.1%), our analysis revealed a relatively good correlation (R 2 ¼ 0.83) between PB and BM samples. However, for low levels of MRD (that is, o0.1%), quantification of the CBFB-MYH11 transcript level appeared to be more sensitive when analyzed in BM compared with PB samples. In 18 samples with undetectable PB MRD, 12 corresponding BM samples were still MRD positive (66%). The BM MRD levels could be up to 133-fold higher than those in the corresponding PB samples. Given the high degree of concordance between BM and PB samples above 0.1%, PB samples could have been included in the study of prognostic significance of MRD using cut-off values of 0.5 and 0.1%.
Median follow-up was 26.5 months (range: 4.6-157). Twoyear percentage of continuous CR (%CCR) was 63% and 2-year overall survival (OS) 88%. Pretreatment CBFB-MYH11 transcript levels had no prognostic impact. MRD1 40.5% was a significant predictor of poorer 2-year %CCR (76% if o0.5% vs 36% if 40.5%, P ¼ 0.01). MRD2 40.1% was also predictive of poorer 2-year %CCR (74% if o0.1% vs 40% if 40.1%, P ¼ 0.02). Moreover, DMRD2 (evaluable in 32 patients) had a strong prognostic impact for %CCR (83% if decrease 43 log vs 28% if decrease o3 log, P ¼ 0.006) (Figure 1a) . Interestingly, the 2-year OS of patients who achieved a decrease in MRD levels greater than 3 log after the first consolidation course was 100%, compared with 67% if MRD decrease was of less than 3 log (P ¼ 0.017). At the end of consolidation treatment, the presence of a detectable MRD3 in PB samples was associated with a 2-year %CCR of 13% compared with 85% in case of undetectable MRD3 (P ¼ 0.0001) (Figure 1b) . In this cohort, no prognostic impact of age, WBC count or additional chromosomal aberrations, including trisomy 22, was found for %CCR. Similarly, mutations of c-KIT, FLT3 or RAS genes, one or all of them, showed no prognostic impact. Analysis of the subset of pediatric patients did not show any significant difference in terms of outcome and molecular response profile compared to adults in our study. We also evaluated the benefit of HD-AraCbased consolidation therapy received by 42 of the 54 patients. HD-AraC consolidation was associated with better %CCR (73 vs 35% in patients who received no HD-AraC, P ¼ 0.03). In multivariate analysis including MRD decrease greater than 3 log after the first course of consolidation therapy and HD-AraC-based consolidation therapy, only molecular response showed a significant prognostic impact on %CCR (relative risk: 6.1 (95% confidence interval: 1.4-26.4)). Because of the low death rate in our cohort, no relevant multivariate analysis on OS could be performed.
In this study, we report the prognostic impact of early MRD detection by RQ-PCR in a relatively large cohort of patients with CBFB-MYH11-positive AML. Molecular response assessed by a reduction of more than 3 log in CBFB-MYH11 transcript level after the first consolidation compared with diagnosis has a strong prognostic impact on %CCR and OS. It also appears as an independent prognostic factor for % CCR in multivariate analysis. Furthermore, in previous series, MRD was assessed at different follow-up time points, most frequently after the end of treatment. [2] [3] [4] An early prediction of prognosis is needed to quickly propose alternative strategies of consolidation. A significant association between relapse risk and CBFB-MYH11 transcript levels after induction or after the first course of consolidation therapy (threshold at 0.1%) has been reported, 3 but no survival analysis was performed. In contrast, Schnittger et al. 5 reported that the kinetics of reduction of the transcript level after the first and second induction cycle and after consolidation treatment had no impact on outcome. In fact, the therapeutic protocol used in that study was different from ALFA protocols, with in particular a double induction therapy followed by autologous stem cell transplantation or by a second course of consolidation therapy. This difference may have contributed to discrepancies with our results. By combining the median expression ratio after consolidation therapy and the 75th percentile of the expression ratio at diagnosis, Schnittger et al. 5 designed a new prognostic score that separated a group with 100% 2-year event-free survival from a significantly worse group. However, this approach does not provide an MRD threshold and is difficult to use in prospective clinical studies. In addition, we showed that the early molecular response alone is sufficient to predict risk of relapse and OS. 
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Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients Numerous clinical and experimental studies in human leukocyte antigen (HLA)-matched stem cell transplantation (SCT) provide evidence that both the graft versus leukemia (GvL) effect and graft versus host disease (GvHD) develop as a result of cellular allo-immune responses evoked by disparity of minor histocompatibility antigens (mHags) between recipient and donor. 1 The mHags are polymorphic peptides that are presented on the cell surface by HLA molecules and can induce allo-immune T-cell responses from mHag-negative donors. The mHags are derived from polymorphic cellular proteins expressed either ubiquitously or in a hematopoietic systemspecific manner. 1 Among hematopoietic mHags, the HLA-A2 restricted mHag HA-1 receives most attention; it is highly immunogenic, is frequent in Caucasians, shows high expression in all types of hematological malignancies and aberrant
